Fontolizumab (planned trade name HuZAF) is a humanized monoclonal antibody[1] and an immunosuppressive drug for the treatment of auto-immune diseases like Crohn's disease.[2] A phase II clinical trial investigating the use for rheumatoid arthritis was terminated because the first phase did not meet the endpoint.[3]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | interferon gamma |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number |
|
ChemSpider |
|
UNII |
|
KEGG |
|
Chemical and physical data | |
Molar mass | ca. 150 kg/mol |
(what is this?) (verify) |